 | Up a level |
Poliaková Turan, Michaela; Riedo, Rahel; Medo, Matúš; Pozzato, Chiara; Friese-Hamim, Manja; Koch, Jonas Paul; Coggins, Si'Ana A; Li, Qun; Kim, Baek; Albers, Joachim; Aebersold, Daniel M; Zamboni, Nicola; Zimmer, Yitzhak; Medová, Michaela (2024). E2F1-associated purine synthesis pathway is a major component of the MET-DNA damage response network. Cancer research communications, 4(7), pp. 1863-1880. American Association for Cancer Research 10.1158/2767-9764.CRC-23-0370
Esposito, Roberta; Lanzos, Andrés; Uroda, Tina; Ramnarayanan, Sunandini; Büchi, Isabel; Polidori, Taisia; Guillen-Ramirez, Hugo; Mihaljevic, Ante; Merlin, Bernard Mefi; Mela, Lia; Zoni, Eugenio; Hovhannisyan, Lusine; McCluggage, Finn; Medo, Matúš; Basile, Giulia; Meise, Dominik F; Zwyssig, Sandra; Wenger, Corina; Schwarz, Kyriakos; Vancura, Adrienne; ... (2023). Author Correction: Tumour mutations in long noncoding RNAs enhance cell fitness. Nature communications, 14(1), p. 5463. Nature Publishing Group 10.1038/s41467-023-41288-5
Dennstädt, Fabio; Glatzer, Markus; Medová, Michaela; Putora, Paul Martin (2023). In Reply to Raaijmakers et al. International journal of radiation oncology, biology, physics, 115(4), p. 1005. Elsevier 10.1016/j.ijrobp.2022.11.019
Orlando, Eleonora; Medo, Matúš; Bensimon, Ariel; Quintin, Aurélie; Riedo, Rahel; Roth, Selina M; Riether, Carsten; Marti, Thomas M; Aebersold, Daniel M; Medová, Michaela; Aebersold, Ruedi; Zimmer, Yitzhak (2023). Correction: An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. Cellular and molecular life sciences : CMLS, 80(4), p. 85. Springer 10.1007/s00018-023-04725-8
Zabini, Adam; Zimmer, Yitzhak; Medová, Michaela (2023). Beyond keratinocyte differentiation: emerging new biology of small proline-rich proteins. Trends in cell biology, 33(1), pp. 5-8. Elsevier 10.1016/j.tcb.2022.08.002
Schanne, Daniel H; Koch, Alexander; Elicin, Olgun; Giger, Roland; Medová, Michaela; Zimmer, Yitzhak; Aebersold, Daniel M (2022). Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy-A Systematic Review. Biomedicines, 10(12) MDPI 10.3390/biomedicines10123288
Melin, Nicolas; Sánchez-Taltavull, Daniel; Fahrner, René; Keogh, Adrian; Dosch, Michel; Büchi, Isabel; Zimmer, Yitzhak; Medová, Michaela; Beldi, Guido; Aebersold, Daniel M.; Candinas, Daniel; Stroka, Deborah (2021). Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury. Cell death & disease, 12(4), p. 366. Nature Publishing Group 10.1038/s41419-021-03654-3
Bosch-Guiteras, Núria; Uroda, Tina; Guillen-Ramirez, Hugo A.; Riedo, Rahel; Gazdhar, Amiq; Esposito, Roberta; Pulido-Quetglas, Carlos; Zimmer, Yitzhak; Medová, Michaela; Johnson, Rory (2021). Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs. Genome research, 31(3), pp. 461-471. Cold Spring Harbor, N.Y 10.1101/gr.265736.120
Bensimon, Ariel; Koch, Jonas P.; Francica, Paola; Roth, Selina M.; Riedo, Rahel; Glück, Astrid A.; Orlando, Eleonora; Blaukat, Andree; Aebersold, Daniel M.; Zimmer, Yitzhak; Aebersold, Ruedi; Medová, Michaela (2020). Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. Molecular oncology, 14(6), pp. 1185-1206. Elsevier 10.1002/1878-0261.12696
Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medová, Michaela (2020). MET targeting: time for a rematch. Oncogene, 39(14), pp. 2845-2862. Springer Nature 10.1038/s41388-020-1193-8
Zimmer, Yitzhak; Reinhardt, Hans Christian; Medová, Michaela (2020). Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology. Frontiers in oncology, 10, p. 611127. Frontiers Research Foundation 10.3389/fonc.2020.611127
Medová, Michaela; Pochon, Benoît; Streit, Bruno; Blank-Liss, Wieslawa; Francica, Paola; Stroka, Deborah; Keogh, Adrian; Aebersold, Daniel M.; Blaukat, Andree; Bladt, Friedhelm; Zimmer, Yitzhak (2013). The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. Molecular cancer therapeutics, 12(11), pp. 2415-2424. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-13-0151
Medová, Michaela; Aebersold, Daniel M; Zimmer, Yitzhak (2012). MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. International journal of cancer, 130(3), pp. 728-34. Malden, Mass.: Wiley-Blackwell 10.1002/ijc.26058
Zimmer, Yitzhak; Vaseva, Angelina V; Medová, Michaela; Streit, Bruno; Blank-Liss, Wieslawa; Greiner, Richard H; Schiering, Nikolaus; Aebersold, Daniel M (2010). Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. Cancer letters, 289(2), pp. 228-36. Amsterdam: Elsevier 10.1016/j.canlet.2009.08.017
Banz, Vanessa M; Medová, Michaela; Keogh, Adrian; Furer, Cynthia; Zimmer, Yitzhak; Candinas, Daniel; Stroka, Deborah (2009). Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3beta. Biochimica et biophysica acta - molecular cell research, 1793(10), pp. 1597-603. New York, N.Y.: Elsevier 10.1016/j.bbamcr.2009.08.002
Ganapathipillai, Suganthini S; Medová, Michaela; Aebersold, Daniel M; Manley, Paul W; Berthou, Sylvie; Streit, Bruno; Blank-Liss, Wieslawa; Greiner, Richard H; Rothen-Rutishauser, Barbara; Zimmer, Yitzhak (2008). Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer research, 68(14), pp. 5769-77. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-08-1269
